Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Free Cash Flow (2016 - 2025)

Heron Therapeutics' Free Cash Flow history spans 14 years, with the latest figure at -$9.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 26.04% year-over-year to -$9.2 million; the TTM value through Dec 2025 reached -$27.9 million, down 18.26%, while the annual FY2025 figure was -$27.9 million, 15.16% down from the prior year.
  • Free Cash Flow reached -$9.2 million in Q4 2025 per HRTX's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $2.9 million in Q3 2024 to a low of -$63.3 million in Q2 2021.
  • Average Free Cash Flow over 5 years is -$23.3 million, with a median of -$18.8 million recorded in 2023.
  • The largest YoY upside for Free Cash Flow was 129.48% in 2024 against a maximum downside of 663.17% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$45.6 million in 2021, then rose by 16.87% to -$37.9 million in 2022, then soared by 105.81% to $2.2 million in 2023, then plummeted by 663.17% to -$12.4 million in 2024, then increased by 26.04% to -$9.2 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Free Cash Flow are -$9.2 million (Q4 2025), $1.3 million (Q3 2025), and -$11.1 million (Q2 2025).